Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide plus ADT before radical prostatectomy in high-risk localized or locally advanced prostate cancer
2023-506153-38-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Apalutamide + ADT with Placebo + ADT (2 arms). Primary endpoints: Pathologic complete response rate and Metastasis-free survival. Planned start Oct 2023; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-506153-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506153-38-00.